Apremilast

Apremilast

Apremilast (trade name: Otezla) is a selective inhibitor of the enzyme phosphodiesterase 4 (PDE4) and inhibits spontaneous production of TNF-alpha from human rheumatoid synovial cells. Apremilast is usded for the treatment of certain types of psoriasis and psoriatic arthritis. It may also be useful for other immune system related inflammatory diseases. Apremilast has been approved by the U.S Food and Drug Administration on May 21, 2014.

Specifications

Product Name:                  Apremilast

Synonyms:                         CC-10004

CAS Number:                     608141-41-9

Molecular Weight:            460.5008

Molecular Formula:          C22H24N2O7S

Purity (HPLC):                     ≥99%.5

Shipping Conditions:         Room temperature.

Storage Conditions:           Refrigerated.

Regulatory Statement:      For Research Use Only.

SMILES:                               CCOc1cc(ccc1OC)[C@H](N1C(=O)c2c(C1=O)c(ccc2)NC(=O)C)CS(=O)(=O)C

  • $300.00
  • Ex Tax: $300.00

Available Options